Jagsonpal Pharmaceuticals logo

Jagsonpal Pharmaceuticals financials: balance sheet, profit and loss, cash flow

NSE: JAGSNPHARMBSE: 507789Pharmaceuticals & BiotechnologySmall Cap

Jagsonpal Pharmaceuticals Limited · Face value ₹2 · Listed May 1987 on BSE, Mar 2000 on NSE
Last close ₹216.09down ₹5.85 (2.64%)BSE ₹216.90

Share price at the NSE close on 30 Oct 2026. Previous close ₹221.94.

30 Oct: open ₹222.00, high ₹226.64, low ₹212.58

52-week range of traded prices to 30 Oct 2026
₹155.00Low, 22 Jan 2026₹264.50High, 30 Jun 2026
Market cap
₹1,427 Cr1,360th largest listed
P/E
31.38
P/B
5.93
Dividend yield
1.85%
ROE
18.3%
ROCE
21.7%
Debt to equity
0.00
Volume, NSE
71,54749.3% delivered

Jagsonpal Pharmaceuticals' financial statements for the 10 years to Mar 2026, standalone: the listed company alone, without its subsidiaries, with the half year to Sep 2026 after them. It had no borrowings at 30 Sep 2026.

10 years at a glance

₹ crore, years to March.Jagsonpal Pharmaceuticals annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
  • Loss
14412Mar 17127−12Mar 181677.23.8Mar 191597.94.7Mar 20188176.8Mar 21226200Mar 22237270Mar 23209220Mar 24269550Mar 25287430Mar 26
Peak revenue ₹287 Cr, year to Mar 2026; lowest ₹127 Cr, year to Mar 2018A loss in 1 of the 10 years shown

Operating and net margin, per cent

  • Operating margin
  • Net margin
20.6%−9.1%4.3%−8.8%5.6%5.4%10.2%11.4%14.4%11.1%19.0%20.2%8.2%−9.1%4.3%5.0%9.1%8.7%11.3%10.8%20.6%15.0%Mar 17Mar 19Mar 21Mar 23Mar 25Mar 26

Results for the year to Mar 2026

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

From revenue to net profit

  1. Revenue287
  2. Materials and goods−104
  3. Employee costs−71
  4. Other expenses−54
  5. Operating profit58
  6. Depreciation−9.4
  7. Other income+12
  8. One-off items−2.1
  9. Finance costs−1.0
  10. Profit before tax58
  11. Tax−14
  12. Net profit43

What the company owns

  • Plant, investments and other assets₹179 Cr
  • Cash and bank₹106 Cr
  • Receivables₹17 Cr
  • Inventory₹15 Cr

What pays for it: net worth and liabilities

  • Net worth₹276 Cr
  • Other liabilities₹29 Cr
  • Owed to suppliers₹12 Cr

Profit and loss

Standalone, ₹ crore, years to March. The last column is the twelve months to Sep 2026, the latest four quarters added.Jagsonpal Pharmaceuticals quarterly results

₹ croreMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Filed 6 MayMar 2026Filed 27 AprSep 2026Twelve monthsFiled 28 Oct
Revenue from operations144127167159188226237209269287301
138138157150169200203186218229239
Materials and goods bought596173568196938096104108
Employee costs–42475054585648717178
Other expenses–35384334475357505453
Operating profit before depreciation6−119919263423515861
Operating margin4.3%−8.8%5.6%5.4%10.2%11.4%14.4%11.1%19.0%20.2%20.4%
Materials, % of revenue–48.3%43.7%35.4%43.0%42.4%39.3%38.3%35.9%36.3%35.9%
Employee costs, % of revenue–33.1%27.9%31.8%28.7%25.5%23.8%23.2%26.4%24.6%25.9%
Other expenses, % of revenue–27.4%22.8%27.4%18.1%20.7%22.4%27.4%18.7%18.8%17.8%
Depreciation and amortisation20111212899
Operating profit after depreciation4−118718243321434953
Other income0013436981211
Finance costs31111001111
Profit before one-off items and tax2−129922273830506063
One-off items13–0000−3020−2−2
Profit before tax14−129922273530705861
30225887141415
Net profit12−127817202722554345
Other comprehensive income––0001−90000
Total comprehensive income––7817211723564346
Net margin8.2%−9.1%4.3%5.0%9.1%8.7%11.3%10.8%20.6%15.0%15.1%
Materials, employee costs and other expenses are shown for the years they add up to operating expenses; for the year to Mar 2017 they do not, so they are left blank.
Earlier years, Mar 2008 to Mar 2016
₹ croreMar 2008Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016
Revenue from operations150136140161177166144138144
137121124146160––129132
Materials and goods bought917976838586656959
Employee costs2020243237––3238
Other expenses2622253139––2935
Operating profit before depreciation1315161517––912
Operating margin8.6%11.3%11.3%9.0%9.4%––6.3%8.6%
Materials, % of revenue60.8%57.9%54.1%51.6%47.9%––49.7%41.0%
Employee costs, % of revenue13.4%14.5%17.0%20.0%20.7%––23.2%26.3%
Other expenses, % of revenue17.1%16.3%17.6%19.4%22.0%––20.7%24.1%
Depreciation and amortisation21223––33
Operating profit after depreciation1114141214––69
Other income000000000
Finance costs653345545
Profit before tax510119103324
Tax241231011
Net profit369772213
Net margin2.0%4.5%6.6%4.5%4.2%1.1%1.5%0.8%2.3%
Standalone, ₹ crore, years to March.

Balance sheet

Standalone, ₹ crore, at 31 March. The last column is the half year to Sep 2026, after the latest full year: the balance sheet at its end.

₹ croreMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Filed 6 MayMar 2026Filed 27 AprSep 2026Half yearFiled 28 Oct
104111122131159187240276244
Share capital131313131313131313
Reserves9198109118146174227263231
457000000
283340342819262840
3323811121212
Total assets136147164168195217278317295
385244583018117174130
9895120111165199161143166
Net debt−35−33−53−48−115−148−129−106−114
Borrowings are counted again inside the liabilities due within a year and after a year. Plant in use and plant being built are given for full years only. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Cash flow

Standalone, ₹ crore, years to March. The last column is the half year to Sep 2026, after the latest full year: the cash flow over its six months.

₹ croreMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Filed 6 MayMar 2026Filed 27 AprSep 2026Half year
28.25.640.135.255.346.826.2
29.114.247.443.763.458.733.2
10.8−14.2−2.712.24.0−0.6−4.1
Receivables8.8−2.9−5.69.2−2.2−4.0−9.8
Inventories0.40.09.15.30.00.5−4.8
Payables6.3−1.8−2.0−9.02.11.83.2
Other working capital−4.8−9.5−4.26.84.11.07.2
Tax paid−3.2−7.5−7.3−8.5−8.1−11.9−7.0
Interest paid−0.60.00.00.00.00.00.0
Capital spending0.50.50.30.20.30.00.1
Free cash flow27.85.139.834.955.046.826.1
−2.3−26.2−51.6−24.5−45.1−35.645.6
−6.8−12.30.0−8.9−11.7−12.1−62.7
Dividends paid2.610.50.0–––26.4
Shares bought back0.00.00.00.00.00.0–
Shares issued0.00.00.00.00.00.04.9
Net change in cash19.1−32.9−11.51.7−1.5−1.09.1
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2017, Mar 2018, Mar 2019 and Mar 2020. Dividends paid is left blank for the years to Mar 2024, Mar 2025 and Mar 2026: the cash-flow statement states no dividends paid, while the company's own dividend record shows one paid in the period, so the line is not given. Shares bought back is left blank for the six months to Sep 2026: the cash-flow statement states no buyback, while the company bought back shares in a tender offer that closed in the period, so the line is not given.

Per share

Standalone, ₹ per share, years to March.Jagsonpal Pharmaceuticals dividend history

₹ per shareMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Filed 6 MayMar 2026Filed 27 Apr
₹1.81−₹1.76₹1.10₹1.20₹2.60₹2.99₹4.08₹3.40₹8.26₹6.40
As stated that year₹4.53−₹4.41₹2.75₹3.00₹6.51₹7.48₹10.20₹8.49₹8.26₹6.40
₹1.81−₹1.76₹1.10₹1.20₹2.60₹2.99₹4.08₹3.38₹8.22₹6.31
₹0.04₹0.04₹0.10₹0.20₹0.40₹1.60₹2.00₹2.00₹2.50₹4.00
––₹15.96₹16.95₹18.63₹19.99₹24.26₹28.35₹36.14₹41.24
Dividend payout2.2%–9.1%16.6%15.3%53.5%49.0%58.8%30.0%62.2%
Shareholder yield––––1.3%1.3%0.0%–––
Market cap at the year end (₹ crore)1007069462098217597271,4411,229
Every year is restated for later splits and bonuses, so they do not break the line. The figure the company stated that year is under each line it differs from. Shareholder yield is left blank for the years to Mar 2024, Mar 2025 and Mar 2026: the cash-flow statement states no dividends paid, while the company's own dividend record shows one paid in the period, so the line is not given.

Ratios

Standalone, years to March.Jagsonpal Pharmaceuticals PE ratio and valuation

RatioMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Filed 6 MayMar 2026Filed 27 Apr
Revenue growth0.1%−12.2%31.8%−5.0%18.5%20.3%4.7%−11.8%28.8%6.9%
Operating profit growth−50.3%––−8.6%123.6%35.2%32.4%−32.5%121.4%13.7%
Net profit growth264.6%––9.1%116.7%14.8%36.4%−15.9%146.5%−22.2%
Earnings per share growth–––9.1%117.0%14.9%36.4%−16.8%143.2%−22.5%
––6.9%7.3%14.6%15.5%18.4%13.0%25.9%16.7%
–––0.4 pts7.3 pts0.9 pts2.9 pts−5.5 pts12.9 pts−9.2 pts
From the net margin–––1.0 pts6.1 pts−0.7 pts4.7 pts−0.9 pts11.9 pts−7.0 pts
From asset turnover–––−0.7 pts1.0 pts1.8 pts−0.8 pts−3.9 pts1.8 pts−2.1 pts
From borrowing–––0.1 pts0.3 pts−0.2 pts−0.9 pts−0.7 pts−0.7 pts−0.1 pts
Return on capital employed––7.7%6.4%14.0%18.5%20.7%11.4%17.9%17.6%
Cash conversion––––165.4%28.6%150.3%156.6%99.9%108.7%
Interest cover1.6–11.214.435.085.179.826.344.847.3
Debt to equity––0.040.040.060.000.000.000.000.00
Receivable days––4549252532191822
Inventory days––16419113411381685851
Payable days––5976826264353740
Cash conversion cycle, days––150164777649533933
Working capital days––766652463456911
Asset turnover––1.231.121.211.361.301.011.090.97
Assets per rupee of net worth––1.301.311.341.321.251.191.161.15
Sales per rupee of plant––7.727.198.0510.1112.90229.34439.80500.39
Capital spending to depreciation––––0.430.310.260.150.040.00
Plant being built, % of plant in use––8.8%8.6%0.0%0.0%0.0%0.0%0.0%0.0%
Interest cover is left blank for the year to Mar 2018: operating profit after depreciation is a loss, and a loss covers no interest bill. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Standalone: the listed company alone, without its subsidiaries. Each window ends with the year to Mar 2026.

Return on assets, latest year
14.5%
Cash from operations against operating profit
80.6%
Measure10 years5 years3 years
Revenue growth, yearly rate7.1%8.9%6.7%
Profit growth, yearly rate29.5%20.4%17.3%
Return on equity, average–17.9%18.5%
Return on capital employed, average–17.2%15.6%
Operating margin, average9.3%15.2%16.8%
Net margin, average8.4%13.3%15.5%
Asset turnover, average–1.151.02
Cash conversion cycle, days, average–5041
Interest cover, average38.456.739.5
Debt to equity, average–0.000.00

Where the cash came from and went

Standalone: the listed company alone, without its subsidiaries. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations18313747
Cash from investing−183−105−36
Cash from financing−45−33−12
Capital spending110
Shares bought back000
Shares issued for cash000
Borrowings raised000
Borrowings repaid000

Accounting checks

Standalone, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9––––788553
Altman Z-scorePublished threshold 1.81––4.343.516.0716.5116.3318.3326.1221.37
Beneish M-scorePublished threshold −1.78––––−3.26−1.54−2.57−3.08−0.57−2.13
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets––––−5.7224.1721.025.7518.2510.73
Cash from operations to profit, 3 yearsPublished threshold 0.7 times––––––1.171.181.251.14
Receivables growth less revenue growthOur threshold 0 percentage points–––8.34−59.502.7129.29−35.70−8.4423.58
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–––12.57−42.40−18.52−27.68−13.37−19.23−11.89
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–––0.306.28−0.44−3.588.14−7.920.37
Assets under construction, years of additionsOur threshold 2 years of additions–––1.210.000.00––0.000.00
Effective tax ratePublished threshold 17.16 per cent17.59–19.8516.4022.0128.3023.2324.7920.7525.10
Tax charged less tax paid, % of profitOur threshold 10 percentage points–––––0.852.33−3.719.104.41
A threshold marked as ours has no published figure; it is the line we read the check against.